NASDAQ: GLPG
Galapagos Nv Stock

$26.92+0.05 (+0.19%)
Updated Apr 29, 2025
GLPG Price
$26.92
Fair Value Price
N/A
Market Cap
$1.77B
52 Week Low
$22.36
52 Week High
$31.23
P/E
N/A
P/B
0.57x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.46
Operating Cash Flow
N/A
Beta
0.62
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

GLPG Overview

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis. In addition, its other pipeline products include GLPG2737, a cystic fibrosis transmembrane conductance regulator that is in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease; and GLPG0555, a JAK1 inhibitor, which is in Phase 1b for treatment of patients with osteoarthritis. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine GLPG's potential to beat the market

DSell
  • Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More

Zen Rating Component Grades

C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
GLPG
Ranked
#343 of 462

Top Ranked Stocks in Industry

View Top Biotech Stocks

Be the first to know about important GLPG news, forecast changes, insider trades & much more!

GLPG News

Overview

Due Diligence Score

Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how GLPG scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

GLPG is good value based on its book value relative to its share price (0.57x), compared to the US Biotechnology industry average (4.37x)
P/B vs Industry Valuation
GLPG's short-term assets ($3.95B) exceed its short-term liabilities ($496.64M)
Short-term Liabilities Financials
GLPG's short-term assets ($3.95B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
There are 30 more GLPG due diligence checks available for Premium users.

Valuation

GLPG fair value

Fair Value of GLPG stock based on Discounted Cash Flow (DCF)

Price
$26.92
Fair Value
-$22.82
Undervalued by
217.98%

GLPG price to earnings (PE)

For valuing profitable companies with steady earnings

Company
0x
Industry
-158.75x
Market
29.19x

GLPG price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
0.57x
Industry
4.37x
GLPG is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

GLPG's financial health

Profit margin

Revenue
$148.0M
Net Income
-$166.7M
Profit Margin
-112.7%

Assets to liabilities

Assets
$4.4B
Liabilities
$1.4B
Debt to equity
0.46
GLPG's short-term assets ($3.95B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
GLPG's short-term assets ($3.95B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
GLPG's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
GLPG's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$46.7M
Investing
$92.1M
Financing
-$1.1M

GLPG vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
GLPGD$1.77B0.00%N/A0.57x
TVTXC$1.78B+3.64%-4.92x30.16x
BCRXC$1.76B+4.86%-19.63x-3.71x
ARQTB$1.75B+1.08%-12.72x11.11x
IDYAC$1.72B+2.18%-5.86x1.63x

Galapagos Nv Stock FAQ

What is Galapagos Nv's quote symbol?

(NASDAQ: GLPG) Galapagos Nv trades on the NASDAQ under the ticker symbol GLPG. Galapagos Nv stock quotes can also be displayed as NASDAQ: GLPG.

If you're new to stock investing, here's how to buy Galapagos Nv stock.

What is the 52 week high and low for Galapagos Nv (NASDAQ: GLPG)?

(NASDAQ: GLPG) Galapagos Nv's 52-week high was $31.23, and its 52-week low was $22.36. It is currently -13.79% from its 52-week high and 20.39% from its 52-week low.

How much is Galapagos Nv stock worth today?

(NASDAQ: GLPG) Galapagos Nv currently has 65,897,071 outstanding shares. With Galapagos Nv stock trading at $26.92 per share, the total value of Galapagos Nv stock (market capitalization) is $1.77B.

Galapagos Nv stock was originally listed at a price of $50.50 in May 14, 2015. If you had invested in Galapagos Nv stock at $50.50, your return over the last 9 years would have been -46.69%, for an annualized return of -6.75% (not including any dividends or dividend reinvestments).

How much is Galapagos Nv's stock price per share?

(NASDAQ: GLPG) Galapagos Nv stock price per share is $26.92 today (as of Apr 29, 2025).

What is Galapagos Nv's Market Cap?

(NASDAQ: GLPG) Galapagos Nv's market cap is $1.77B, as of May 1, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Galapagos Nv's market cap is calculated by multiplying GLPG's current stock price of $26.92 by GLPG's total outstanding shares of 65,897,071.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.